Kevin T. Conroy - Jul 1, 2022 Form 4 Insider Report for EXACT SCIENCES CORP (EXAS)

Role
President and CEO, Director
Signature
/s/ Kevin T. Conroy by Mark R. Busch, attorney-in-fact
Stock symbol
EXAS
Transactions as of
Jul 1, 2022
Transactions value $
$15,265
Form type
4
Date filed
7/6/2022, 04:11 PM
Previous filing
Jul 5, 2022
Next filing
Aug 16, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EXAS Common Stock Award $15.6K +328 +0.03% $47.41 1.17M May 2, 2022 Direct F1
transaction EXAS Common Stock Sale -$285 -7 0% $40.75 1.17M Jul 1, 2022 Direct F2, F3
holding EXAS Common Stock 26.9K Jul 1, 2022 Held in 401(k) Plan
holding EXAS Common Stock 21.7K Jul 1, 2022 Held in Grantor Retained Annuity Trust
holding EXAS Common Stock 21.7K Jul 1, 2022 Held in Grantor Retained Annuity Trust
holding EXAS Common Stock 21.7K Jul 1, 2022 Held in Grantor Retained Annuity Trust
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares of common stock purchased through Employee Stock Purchase Plan.
F2 The sale reported in this field was effected pursuant to a Rule 10b5-1 trading plan, which was disclosed via Form 8-K filed by Exact Sciences Corporation with the U.S. Securities and Exchange Commission on November 27, 2020. This particular sale was effected by the broker-dealer administering the plan to correct a typo made in a prior sale order initiated pursuant to the plan.
F3 In addition to the shares of Common Stock reported on this Form 4, which total 1,260,032 shares, Mr. Conroy also holds, in the aggregate, an additional 761,441 vested and unvested options to purchase shares of Common Stock and restricted stock units, with each restricted stock unit representing a contingent right to receive one share of Common Stock.